Pasteurized
Akkermansia muciniphila
AKK PROBIO
ameliorates inflammation and metabolic disorder in
db/db
mice with alterations
Mengling Chen, Rao Li, Yangling Xiang, Xin Ma, Xueping Yu, Jingqi Zhao, Dayong Ren Abstract
BACKGROUND
Diabetes mellitus, especially type 2 diabetes mellitus (T2DM), represents a significant global health challenge. Growing evidence indicates that Akkermansia muciniphila , a promising next‐generation beneficial microorganism, could help alleviate metabolic disorders. Nevertheless, its strain‐specific effects and associated mechanisms require further investigation. Here, we investigated the potential effects of pasteurized A. muciniphila AKK PROBIO in T2DM using db/db mice.
RESULTS
Our findings show that pasteurized AKK PROBIO supplementation was associated with lower fasting glucose levels, reduced inflammatory markers, and improved cholesterol balance in db/db mice. Pasteurized AKK PROBIO administration was accompanied by changes in gut microbiota composition, including enrichment of bacterial taxa linked to short‐chain fatty acid (SCFA) production, and by increased GLP‐1 levels and altered serum metabolites, including 9,9′‐di‐ cis ‐ζ‐carotene and
CONCLUSIONS
Taken together, our findings indicate that pasteurized AKK PROBIO ameliorates metabolic disorder and inflammation in db/db mice, accompanied by changes in gut microbial ecology, serum metabolites, and hepatic inflammatory/lipid metabolic signaling. This study supports pasteurized A. muciniphila AKK PROBIO as a postbiotic for further investigation in metabolic disorders. © 2026 Society of Chemical Industry.